KR960006924A - Diltiazem sustained release formulation - Google Patents

Diltiazem sustained release formulation Download PDF

Info

Publication number
KR960006924A
KR960006924A KR1019940019516A KR19940019516A KR960006924A KR 960006924 A KR960006924 A KR 960006924A KR 1019940019516 A KR1019940019516 A KR 1019940019516A KR 19940019516 A KR19940019516 A KR 19940019516A KR 960006924 A KR960006924 A KR 960006924A
Authority
KR
South Korea
Prior art keywords
diltiazem
pharmacologically acceptable
sustained release
water
polymer
Prior art date
Application number
KR1019940019516A
Other languages
Korean (ko)
Inventor
이정상
유상현
류길수
김현진
Original Assignee
이웅열
주식회사 코오롱
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이웅열, 주식회사 코오롱 filed Critical 이웅열
Priority to KR1019940019516A priority Critical patent/KR960006924A/en
Publication of KR960006924A publication Critical patent/KR960006924A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 딜티아젬 또는 약리적으로 허용되는 그 염을 함유하는 1일 1회 복용의 틸티아젬의 서방성 제형에 관한 것으로, 구형 코어; 이 구형 코어에 코팅되는 딜티아젬, 결합제 및 딜테아젬과 이온결합이 가능한 약리학상 허용되며 장관의 생리적 pH에서 음전하를 가지는 고분자로 이루어진 혼합 약물층;이 약물함유층 외부에 1층 이상의 다중막으로 수용성 혹은 수불용성 폴리머의 단독 또는 혼합물의 멤브레인층으로 이루어진다.The present invention relates to a sustained release formulation of tiltiazem once daily containing diltiazem or a pharmacologically acceptable salt thereof, comprising: a spherical core; Pharmacologically acceptable pharmacologically acceptable mixed drug layer capable of ion bonding with diltiazem, a binder, and dilteaze coated on the spherical core; a mixed drug layer consisting of a negatively charged polymer at the physiological pH of the intestine; It consists of a membrane layer of singly or a mixture of water-soluble or water-insoluble polymers.

본 발명은 딜티아젬의 짧은 반감기와 빠른 흡수로 인해 약효유지시간이 짧아져 자주 복용해야 하는 단점을 보완하고 고단위 처방에 의해 높은 유효 혈중농도를 유지시켜서 협십증 및 중증 고혈압과 같은 환자로 하여금 1일1회 복용으로도 충분한 약효를 유지할 수 있게 하며, 단일한 펠렛으로 간단히 제조되는 신규 서방성 펠렛을 제공한다.The present invention shortens the drug retention time due to the short half-life and rapid absorption of diltiazem, thereby compensating for the disadvantages of frequent intake and maintaining high effective blood concentrations by high-prescription therapy, thereby allowing patients such as angina and severe hypertension. It is possible to maintain sufficient medicinal effects even once a day, and to provide novel sustained release pellets which are simply prepared into a single pellet.

Description

딜티아젬 서방형 제형Diltiazem sustained release formulation

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (4)

구형의 코어 물질 위에 딜티아젬 또는 약리학적으로 허용되는 그의 염, 결합제 및 장관의 생리적 pH에서 음전하를 가지는 약리학적으로 허용되는 고분자물질로 이루어진 약물함유층과, 그 위에 수용성 또는 수불용성 폴리머를 단독 또는 혼합으로 다중 코팅한 멤브레인층으로 이루어진 딜티아젬의 서방성 제형.A drug-containing layer of diltiazem or a pharmacologically acceptable salt thereof, a binder, and a pharmacologically acceptable polymer material having a negative charge at the physiological pH of the intestinal tract, and a water-soluble or water-insoluble polymer on the spherical core material alone or Sustained release formulation of diltiazem consisting of a membrane layer multi-coated by mixing. 제1항에서, 전체 펠렛에 대하여 딜티아젬의 함량이 20-80중량%이고, 고분자물질이 5-30중량%인 것을 특징으로 하는 제형.The formulation of claim 1, wherein the content of diltiazem is 20-80% by weight and the polymer is 5-30% by weight based on the total pellets. 제1항 또는 2항에서, 고분자물질이 관능기로 카복시기를 가지는 것을 특징으로 하는 제형.The formulation according to claim 1 or 2, wherein the polymer has a carboxyl group as a functional group. 제3항에 있어서, 고분자물질이 폴리메틸메타크릴레이트, 카복시메틸셀룰로스 또는 하이드록시프플필셀룰로스석시네이트임을 특징으로 하는 제형.4. The formulation according to claim 3, wherein the polymer is polymethylmethacrylate, carboxymethylcellulose or hydroxypropyl cellulose succinate. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940019516A 1994-08-08 1994-08-08 Diltiazem sustained release formulation KR960006924A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019940019516A KR960006924A (en) 1994-08-08 1994-08-08 Diltiazem sustained release formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940019516A KR960006924A (en) 1994-08-08 1994-08-08 Diltiazem sustained release formulation

Publications (1)

Publication Number Publication Date
KR960006924A true KR960006924A (en) 1996-03-22

Family

ID=66697659

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940019516A KR960006924A (en) 1994-08-08 1994-08-08 Diltiazem sustained release formulation

Country Status (1)

Country Link
KR (1) KR960006924A (en)

Similar Documents

Publication Publication Date Title
KR100535319B1 (en) Drug composition with controlled drug release rate
EP0226884B1 (en) System for the controlled-rate release of active substances
TW577758B (en) Intra-articular preparation for the treatment of arthropathy
US6417227B1 (en) Methods of delivery of cetyl myristoleate
NZ263632A (en) Oral sustained release morphine composition having a barrier coating comprising at least one water insoluble compound
US20080069848A1 (en) Device, method, and use for treatment of neuropathy involving nitric oxide
KR930003905A (en) Pharmaceutical binding agents
PL142312B1 (en) Process for preparing delayed-action preparation with bromohexyne
DE60036874D1 (en) PELLET FORMULATION WITH CONTROLLED RELEASE
SK284135B6 (en) Percutaneous delivery system
LV12399A (en) Enhanced once-a-day pulse minicyclic mini-cycling systems
JP2000506133A (en) Nitric oxide donor can reduce drug-induced toxicity
WO1995029666A1 (en) Sustained-release pharmaceutical system for the delivery of antioxidants
EP0136103B1 (en) Amosulalol hydrochloride long acting formulations
KR850700212A (en) Sustained Release Pharmaceutical Wexel
JPH0733682A (en) Novel composite material and sustained-release preparation in which the same material is used as carrier
JPH02501982A (en) Compositions of polymeric diffusion matrices for transdermal administration of pharmaceutical formulations
KR960006924A (en) Diltiazem sustained release formulation
CA2881726A1 (en) Extended release compositions of an aminoalkyl nitrate
KR910007517A (en) Sustained-release preparations of basic pharmaceutical hydrochloride
GB2190287A (en) Oral ketoprofen formulation
JPH0688901B2 (en) Liquid long-term release pharmaceutical composition containing ionic drug
JPH07500332A (en) Novel drug with ion exchanger
Naval Formulation and evaluation of floating microspheres of captopril for prolonged gastric residence time
WO2016197042A1 (en) Modified or targeted release formulations of linaclotide

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application